We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TransCon

News List

The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial prnasia
June 04, 2021
June 1 is World Hypopara Awareness Day. VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs, announced that it has obtained the investigational new drug (IND) approval from the ...
VISEN Pharmaceuticals Receives IND Approval to Initiate Phase 2 Clinical Trial of TransCon ™ CNP in Achondroplasia (ACH) in China prnasia
January 08, 2021
VISEN Pharmaceuticals, a biotech company committed to the treatment of endocrine-related diseases, introducing the world's leading treatment methods and drugs into the China market and hoping to provide more Chinese patients quick access to the ...